EVA-Q

Main information

  • Trade name:
  • EVA-Q 100G POW
  • Pharmaceutical form:
  • POW
  • Composition:
  • 100G
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • EVA-Q 100G POW
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

19-7-2018

Food additive re-evaluation: EFSA workshop in November focuses on foods for infants below 16 weeks of age

Food additive re-evaluation: EFSA workshop in November focuses on foods for infants below 16 weeks of age

Food additive re-evaluation: EFSA workshop in November focuses on foods for infants below 16 weeks of age

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

There are no news related to this product.